Evidence map›Paper›PMID 32524084›Full record

ArticleMolecular Frontiers journal2019

Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU).

Cary O Harding

Abstract read
In one paragraph

Article in Molecular Frontiers journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Cary O HardingDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Mailstop L-103, 3181 Sam Jackson Park Rd., Portland, OR 97239, USA.

Funding

Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive HyperphenylalaninemiaU54HD100982 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI LONGO, NICOLA · 2019 to 2023
$7.9M
Novel therapy for monoamine neurotransmitter deficiency in PKUR01NS080866 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI HARDING, CARY O. · 2012 to 2020
$3.3M
NICHD NIH HHS U54 HD100982NINDS NIH HHS R01 NS080866
6 · The paper itself

Abstract

Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency is among the most common inborn errors of metabolism. Dietary therapy begun early in infancy prevents the major manifestations of the disease but shortcomings to treatment continue to exist including lifelong commitment to a complicated and unpalatable diet, poor adherence to diet in adolescence and adulthood, and consequently a range of unsatisfactory outcomes, including neuropsychiatric disorders, frequently develop. Novel treatments that do not strictly depend upon dietary protein restriction are actively sought. This review discusses the potential for and the limitations of permanently curative cell-directed treatment of PKU, including liver-directed gene therapy and gene editing, if initiated during early infancy. A fictional but realistic vignette of a family with a new baby girl recently diagnosed with PKU is presented. What is needed to permanently cure her?

Indexed as

Gene EditingHepatocyte TransplantationLiver-Directed Gene TherapyPhenylalaninePhenylalanine Hydroxylase DeficiencyPhenylketonuria

Identifiers

PMID32524084
PMCPMC7286632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.